29 August 2024, Bavaria, Munich: The logo of the pharmaceutical company ... The growth rate for its blockbuster drugs – Opdivo, Eliquis, and Orencia – has also slowed lately.

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC). These adult patients ...

Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo. Patients with resectable (surgically unremovable) non-small cell lung cancer ...

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer. The Food and Drug Administration (FDA) has approved neoadjuvant (presurgical) ...

Opdivo’s U.S. patent loss is expected in 2028, Europe in 2030, and Japan in 2031. Another cancer drug, Yervoy (ipilimumab), is expected to lose market exclusivity in 2025 in the U.S. and Japan ...

Risk of disease recurrence or death was reduced by 42% with Opdivo compared to chemotherapy. 18-month event-free survival was 70% for Opdivo-treated patients, versus 50% for chemotherapy.

Treatment with nivolumab reduced the risk of disease recurrence, progression or death by 42% compared with placebo. The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) with ...

1. U.S. Food and Drug Administration approves perioperative treatment of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant single-agent Opdivo for resectable non ...

Last week’s NICE rejection of Opdivo for routine use in lung cancer patients has presented BMS with another setback – and an opportunity for Merck Sharp & Dohme (Merck in the US) and its rival ...

Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain and rash. The ...

September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...

An FDA Advisory Committee on Thursday voted against broader use of immune checkpoint inhibitors Keytruda and Opdivo developed by Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) in certain ...